Advertisement
U.S. markets close in 1 hour 37 minutes
  • S&P 500

    5,253.63
    +5.14 (+0.10%)
     
  • Dow 30

    39,787.70
    +27.62 (+0.07%)
     
  • Nasdaq

    16,381.03
    -18.49 (-0.11%)
     
  • Russell 2000

    2,124.11
    +9.77 (+0.46%)
     
  • Crude Oil

    83.06
    +1.71 (+2.10%)
     
  • Gold

    2,242.30
    +29.60 (+1.34%)
     
  • Silver

    25.00
    +0.24 (+0.98%)
     
  • EUR/USD

    1.0796
    -0.0034 (-0.31%)
     
  • 10-Yr Bond

    4.2040
    +0.0080 (+0.19%)
     
  • GBP/USD

    1.2622
    -0.0016 (-0.12%)
     
  • USD/JPY

    151.4070
    +0.1610 (+0.11%)
     
  • Bitcoin USD

    70,917.76
    +2,527.30 (+3.70%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • Nikkei 225

    40,168.07
    -594.66 (-1.46%)
     

Venus Concept Inc. to Present at the Maxim Virtual Growth Conference on March 28th

Venus Concept Inc.
Venus Concept Inc.

TORONTO, March 21, 2022 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that management will present at the Maxim Virtual Growth Conference, which is being held virtually from March 28th-30th.

Management’s presentation will be available on-demand beginning on Monday, March 28th. The Company will also participate in a panel discussion session titled “Aesthetic Device Industry Panel” on Monday, March 28th at 1:00pm Eastern time.

The panel and presentation will be hosted on Maxim’s M-Vest website and made available to those registered for the conference. Interested parties can register for the conference and view the panel via the following link: https://m-vest.com/events/2022-virtual-growth-conference, and access the Company presentation via: https://m-vest.com/events/2022-virtual-growth-conference/p/vero.

About Venus Concept

Venus Concept is an innovative global medical aesthetic technology leader with a broad product portfolio of minimally invasive and non-invasive medical aesthetic and hair restoration technologies and reach in over 60 countries and 18 direct markets. Venus Concept focuses its product sales strategy on a subscription-based business model in North America and in its well-established direct global markets. Venus Concept’s product portfolio consists of aesthetic device platforms, including Venus Versa, Venus Legacy, Venus Velocity, Venus Fiore, Venus Viva, Venus Glow, Venus Bliss, Venus BlissMAX, Venus Epileve and Venus Viva MD. Venus Concept’s hair restoration systems include NeoGraft®, an automated hair restoration system that facilitates the harvesting of follicles during a FUE process and the ARTAS® and ARTAS iX® Robotic Hair Restoration systems, which harvest follicular units directly from the scalp and create recipient implant sites using proprietary algorithms. Venus Concept has been backed by leading healthcare industry growth equity investors including EW Healthcare Partners (formerly Essex Woodlands), HealthQuest Capital, Longitude Capital Management, and Aperture Venture Partners.

CONTACT: Investor Relations Contact: ICR Westwicke on behalf of Venus Concept: Mike Piccinino, CFA VenusConceptIR@westwicke.com


Advertisement